

Saturated fat, carbohydrates and cardiovascular disease

R.S. Kuipers^{1*}, D.J. de Graaf¹, M.F. Luxwolda¹, M.H.A. Muskiet², D.A.J. Dijck-Brouwer¹, F.A.J. Muskiet¹

¹University Medical Center Groningen, Groningen, the Netherlands, ²VU University Medical Center, Amsterdam, the Netherlands, *corresponding author: tel.:+31 (0)050-3612733, fax: +31 (0)50-3612290, e-mail: remkokuipers@hotmail.com

ABSTRACT

The dietary intake of saturated fatty acids (SAFA) is associated with a modest increase in serum total cholesterol, but not with cardiovascular disease (CVD). Replacing dietary SAFA with carbohydrates (CHO), notably those with a high glycaemic index, is associated with an increase in CVD risk in observational cohorts, while replacing SAFA with polyunsaturated fatty acids (PUFA) is associated with reduced CVD risk. However, replacing a combination of SAFA and *trans*-fatty acids with n-6 PUFA (notably linoleic acid) in controlled trials showed no indication of benefit and a signal toward increased coronary heart disease risk, suggesting that n-3 PUFA may be responsible for the protective association between total PUFA and CVD. High CHO intakes stimulate hepatic SAFA synthesis and conservation of dietary SAFA. Hepatic *de novo* lipogenesis from CHO is also stimulated during eucaloric dietary substitution of SAFA by CHO with high glycaemic index in normo-insulinaemic subjects and during hypocaloric high-CHO/low-fat diets in subjects with the metabolic syndrome. The accumulation of SAFA stimulates chronic systemic low-grade inflammation through its mimicking of bacterial lipopolysaccharides and/or the induction of other pro-inflammatory stimuli. The resulting systemic low-grade inflammation promotes insulin resistance, reallocation of energy-rich substrates and atherogenic dyslipidaemia that concertedly give rise to increased CVD risk. We conclude that avoidance of SAFA accumulation by reducing the intake of CHO with high glycaemic index is more effective in the prevention of CVD than reducing SAFA intake *per se*.

KEYWORDS

Saturated fatty acids, carbohydrates, diet heart, cardiovascular disease, fat

INTRODUCTION

In 2003, in the Netherlands, fat comprised about 34% of total energy intake (en%), and was, after carbohydrates (CHO), the main energy source. Grains, grain products and non-alcoholic beverages are the most important sources of dietary CHO in the Netherlands (*table 1*). Saturated (SAFA), monounsaturated and polyunsaturated fatty acids (PUFA) each constitute approximately 12.9, 10.8 and 7.1 en% of the total fat intake. Milk, milk products and meat are the main sources of dietary SAFA (*table 1*) in the Netherlands,^{1,2} as well as in the United States.³ Fatty acids are pleiotropic nutrients with important functions in the human body in addition to serving as substrates for energy production. Fatty acids are essential components of the phospholipids in all cell membranes, act as carriers of the fat-soluble vitamins A, D, E and K, and include the essential n-3 and n-6 PUFA, alpha-linolenic and linoleic acid, respectively.

The diet-heart hypothesis, also named the diet-heart paradigm, is based on the association between serum cholesterol and dietary SAFA with the risk of cardiovascular disease (CVD) that was found in the Seven Countries Study by Ancel Keys,⁴ and the relationship between dietary SAFA and serum cholesterol that was demonstrated in short⁵ and long-term feeding trials.^{6,7} However, recent evidence from randomised controlled trials (RCTs) and observational studies has provided little support for the diet-heart paradigm and the causality of the association between dietary SAFA and CVD outcomes is increasingly questioned.⁸⁻¹¹

In this paper we discuss the current scientific data on the effects of dietary SAFA, their controversies and the potential underlying (patho)physiological mechanisms for the role of SAFA in CVD.

Table 1. Dietary intakes and the average contributions of different dietary resources in 2003 in a typical Dutch population^{a,b}

	Energy	Protein	Fat	SAFA	MUFA	PUFA	Trans	CHO	MS & DS	PS	Fibre
Total daily intake (kcal and g/day)	2328	81	90	33	28	19	3	277	144	133	19.3
Total daily intake (en%)		14.3	34.4	12.9	10.8	7.1		48.2	24.9	23.1	2.1
Potatoes and other tuberous organs (g%)	3.8	2.9	1.2	1.7	1.0	0.8	3.4	6.2	0.7	12.2	15.1
Vegetables (g%)	1.1	2.2	0.3	0.2	0.5	0	0	1.3	1.6	1.0	12.2
Legumes (g%)	0.1	0.3	0	0		0	0	0.2	0	0.4	1.1
Fruits ^c (g%)	3.9	2.6	3.7	1.9	4.9	6.1	0	4.8	8.2	1.1	12.3
Milk and milk products (g%)	14.5	25.1	18.1	30.8	13.0	2.5	19.8	9.9	17.8	1.3	1.9
Cheese	5.0	9.2	10.7	18.0	7.9	1.5	13.3	0.1	0.2	0	0
Grains and grain products ^d (g%)	23.0	20.8	10.8	6.7	9.2	17.2	25.4	34.0	5.2	65.2	43.0
Bread	16.4	16.9	5.8	3.6	4.1	11.3	3.8	25.3	4.1	48.3	35.9
Meat and meat products ^e (g%)	11.4	29.9	20.1	20.3	25.9	10.3	10.0	0.7	0.2	1.2	0.1
Fish and shellfish (g%)	0.5	2.1	0.6	0.4		0.8	0.2	0.1	0	0.2	0
Eggs (g%)	0.7	1.7	1.3	0.8		1.4	0.1	0	0	0	0
Fats ^f (g%)	6.4	0.1	18.8	14.5	16.5	33.5	13.1	0	0.1	0	0
Sugar and candy (g%)	7.7	1.7	5.2	6.3	5.5	3.6	3.3	11.7	20.6	2.1	3.6
Cookies, cake and biscuits (g%)	7.0	3.2	7.7	9.0	7.2	5.2	18.6	8.3	7.7	8.9	4.7
Non-alcoholic beverages (g%)	8.2	1.6	0.2	0.3	0.1	0	0.1	16.3	30.6	0.8	1.8
Alcoholic beverages (g%)	5.1	1.0	0.1	0.1	0.1	0	0.1	2.9	4.4	1.3	0
Sauces, seasonings, herbs and spices (g%)	4.0	0.9	9.4	4.4	12.3	16.3	0.7	1.5	2.1	0.9	0.8
Soups and bouillon (g%)	0.8	1.3	0.8	0.8		0.8	0.7	0.6	0.3	0.9	1.9
Miscellaneous (g%)	1.7	2.5	1.8	1.9		1.2	4.4	1.5	0.7	2.4	1.4
Total	100	100	100	100	96	96	100	100	100	100	100

a. data derived from the Dutch VCP reference population (n=750) of Dutch men (352) and women (398) between 19-30 years of age in 2003.^{1,2}

b. SAFA = saturated fatty acids; MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids; trans = trans-fatty acids; CHO = carbohydrates; MS = monosaccharides; DS = disaccharides; PS = polysaccharides

c. including seeds and nuts

d. including flour, bread, pasta, rice and cereals

e. including poultry

f. including oils, butter, margarines and other frying fats

LIPOPROTEINS, CHOLESTEROL, SAFA AND CVD

A high serum total cholesterol, and especially LDL cholesterol, is associated with an increased risk of CVD, whereas a high HDL cholesterol has a protective association.¹² The serum total cholesterol/HDL cholesterol ratio is the consensus risk factor for the estimation of coronary heart disease risk. The reduction of this ratio by 1 point is classically associated with a coronary heart disease risk reduction of 52%.¹³ The metabolic syndrome, also called the insulin resistance syndrome, which is characterised by obesity, impaired glucose homeostasis, hypertension and atherogenic dyslipidaemia ('deadly quartet'), is a major risk factor for CVD.¹⁴ Similarly, atherogenic dyslipidaemia,¹⁵ which is characterised by elevated triglycerides, small dense LDL particles and reduced HDL cholesterol ('deadly lipid triad'),¹⁶ is also a major risk factor for CVD. These small dense LDL particles are susceptible to structural modifications by oxidation¹⁷

and notably oxidised LDL particles affect atherosclerotic plaque formation¹⁸ by promoting foam cell generation, endothelial dysfunction and local inflammation.

An increase in the consumption of SAFA by 1 energy percent (en%) raises serum total cholesterol by 0.052 mmol/l.⁶ However, in the same study, the total cholesterol of subjects consuming 15 en% SAFA ranged from 4 to 6 mmol/l, indicating that most variation in the serum total cholesterol is not on account of the differences in SAFA intake *per se*.⁶ Because of the presumed relationship between SAFA and CVD, it is nowadays recommended to replace dietary fat, and especially SAFA, by *cis*-unsaturated fatty acids.^{19,20} Between 1987/1988 and 1997/1998 the intake of *cis*-unsaturated fatty acids, refined CHO and monosaccharides and disaccharides in the Netherlands increased at the expense of fat, SAFA and *trans*-fatty acids.^{19,20} In this review, we will evaluate the current consensus on the relationship between SAFA and CVD while the consequences of replacing SAFA by CHO,

monounsaturates and PUFA will be examined with regard to their influence on atherogenic dyslipidaemia.

SAFA AND CVD

A recent meta-analysis of prospective cohort studies²¹ showed that the intake of SAFA is not associated with an increased risk of coronary heart disease, stroke or those two combined (i.e. cardiovascular disease, CVD), before²¹ or after²² adjustment for serum total cholesterol. Additionally, the consumption of milk and milk products was not related to CVD in a meta-analysis of prospective cohort studies. Consumption of milk and milk products may even decrease CVD risk,²³ although this meta-analysis of prospective cohort studies was not supported by a recent prospective cohort study in the Netherlands.²⁴

REPLACING SAFA BY CHO

Replacing 5 en% SAFA with 5 en% CHO reduced serum total cholesterol by 0.18 mmol/l, LDL cholesterol by 0.16 mmol/l and HDL cholesterol by 0.05 mmol/l, increased the serum triglycerides by 0.11 mmol/l and had no effect on the total cholesterol/HDL cholesterol ratio.³ LDL cholesterol reduction from isocaloric substitution of SAFA by CHO is accompanied by an increase in the amount of atherogenic small dense LDL particles and a decrease in the less atherogenic large LDL particles.¹⁵ Because of the increase in triglycerides and small dense LDL and no change in the total cholesterol/HDL cholesterol ratio, replacing SAFA by CHO seems unfavourable with regard to CVD prevention.

A pooled analysis of 11 cohort studies showed that replacing 5 en% SAFA by CHO was associated with a slightly increased risk of coronary events (7%), but there was no difference in mortality.²⁵ In practice, however, SAFA are often replaced by CHO with a high glycaemic index. A subsequent analysis by Jakobsen *et al.*²⁶ showed that replacement of 5 en% SAFA by CHO with a low glycaemic index was associated with a non-significant reduction in CVD risk, while replacing SAFA by CHO with a high glycaemic index was associated with a 33% increased risk of myocardial infarction.²⁶

REPLACING SAFA BY MONOUNSATURATED FATTY ACIDS

Replacing 5 en% SAFA by 5% monounsaturated fatty acids reduced total cholesterol by 0.21 mmol/l, LDL cholesterol by 0.20 mmol/l, and HDL cholesterol by 0.01

mmol/l, and increased the serum triglycerides by 0.01 mmol/l. The 0.145 reduction in the total cholesterol/HDL cholesterol ratio is predicted to translate into a coronary heart disease risk reduction of 7.5%.¹³ However, in the recent pooled analysis of prospective observational cohorts by Jakobsen *et al.*,²⁶ the intake of monounsaturated fatty acids was associated with a 19% higher risk of CVD events, but not with coronary heart disease mortality. This outcome contrasts with the beneficial effects of the so-called Mediterranean diet, which is typically high in monounsaturated fatty acids,²⁷ and the theoretical decrease of the total cholesterol/HDL cholesterol ratio, when SAFA are replaced by monounsaturated fatty acids.⁵ Consequently, it was recently concluded that there is insufficient evidence to advise the replacement of SAFA by monounsaturated fatty acids.²⁸

REPLACING SAFA BY N-6 AND N-3 PUFA

Replacing 5 en% SAFA by 5 en% PUFA decreased total cholesterol by 0.29 mmol/l, LDL cholesterol by 0.26 mmol/l, HDL cholesterol by 0.02 mmol/l, triglycerides by 0.03 mmol/l and the total cholesterol/HDL cholesterol ratio by 0.175, which theoretically corresponds to a coronary heart disease risk reduction of 9.1%.¹³ A pooled analysis of 11 cohort studies showed that replacement of 5 en% SAFA by (n-3 and n-6) PUFA was associated with a significant 13% reduction in coronary events and a 26% reduction in coronary heart disease mortality.²⁵ These results are consistent with a meta-analysis of RCTs,^{29,30} which showed that replacing 5 en% SAFA by (n-3 and n-6) PUFA reduced coronary heart disease risk by 10%. These results have been interpreted as providing strong concordant evidence to support current recommendations to replace SAFA with the n-6 PUFA linoleic acid, and were recently translated into an American Heart Association (AHA) advice,³¹ to consume 'at least 5 to 10 % of energy as n-6 PUFA'. Importantly, however, neither of these pooled analyses made a clear distinction between n-6 and n-3 PUFA species, and the Mozaffarian *et al.*²⁹ meta-analysis of RCTs did not consider the potential confounding role of *trans*-fatty acids. The n-3 PUFA³² and *trans*-fatty acids³³ have been positively and negatively related to CVD development, respectively. If distinction is made between interventions that selectively replaced SAFA and *trans*-fatty acids with n-6 PUFA/linoleic acid, and those that substantially increased both n-3 and n-6 PUFAs, a whole different picture emerges.³⁴ Linoleic acid selective PUFA interventions produced no indication of benefit but rather a fairly consistent, but non-significant, signal toward *increased* risk of coronary heart disease and death.

These potentially negative effects of n-6 PUFA acid may even have been underestimated, since PUFA also replaced *trans*-fatty acids. If SAFA is replaced by both n-3 and n-6 PUFA, a significant (22%) decreased coronary heart disease risk is found. However, this reduction may also be attributable, at least in part, to the reduced consumption of *trans*-fatty acids.³⁴

RISK REDUCTION IN PERSPECTIVE

Besides the already mentioned large variability in the relationship between serum total cholesterol and SAFA intake,⁶ there is the well-known example of the African Maasai who had very high intakes of both cholesterol (500 to 2000 mg/day) and SAFA from milk,^{35,36} but exhibited remarkably low serum cholesterol levels^{8,11,35,36} and although accompanied by extensive atherosclerosis, with lipid infiltration and fibrous changes, they had a very low incidence of cardiovascular events.⁸ Secondly, comparison with other risk factors and the feasibility of a reduced SAFA consumption also require some attention. In 2003 the average SAFA intake in the Netherlands was estimated at 12.9% of total energy (en%). This intake should be lowered by 38%, i.e. to 7.9 en%, to achieve a 10% risk reduction in CVD.³⁰ The Dutch National Institute for Public Health and the Environment (RIVM) calculated that a 5% reduction in SAFA intake would reduce the annual incidence of CVD by 4300 persons per year and CVD mortality by 1000 people per year,³⁷ at an annual mortality from CVD of approximately 40,000/year in the Netherlands.³⁸ For comparison, the estimated mortality attributable to overweight, insufficient fruit and vegetable intake, and low fish intake is 6900, 7300, and 4500 persons per year, respectively.³⁷ A recent report from the UK predicted that an increase in the intake of fruits and vegetables from 279-356 g to 440 g/day would save as many lives as a reduction in the current SAFA consumption in the UK from >14 to 3 en% and a reduction in salt intake from >8.1 to 3.5 g/day.³⁹ Consequently, other risk factors seem much simpler to be addressed and their role seems at least comparable, if not more important, in the current high incidence of CVD. Recommendations to increase intake of n-3 PUFA, fruit and vegetables and reduce sodium intake,³⁰ to increase physical activity,⁴⁰ to reduce *trans*-fatty acid intake³⁰ and reduce the intakes of CHO with high glycaemic index, such as notably found in soft drinks and candy (*table 1*), seem more prudent candidates in the battle against CVD⁴¹ than to reduce SAFA intake to the recommended <10 en%^{19,20}, and also because in daily practice SAFA are mostly replaced by CHO with high glycaemic index.⁴²

RELATION BETWEEN INFLAMMATION AND LIPOPROTEIN METABOLISM

The causal relationship between LDL cholesterol *per se* and CVD⁶ is still subject of debate.⁸⁻¹¹ However, both oxidised and small dense LDL have been related to increased CVD risk.^{17,18} Moreover, there is convincing evidence that the LDL cholesterol reducing statins reduce CVD risk,⁴³⁻⁴⁶ but statins have pleiotropic effects. Statins also have anti-inflammatory effects and equally reduce C-reactive protein (CRP) and the concentration of LDL cholesterol.⁴³⁻⁴⁷ This observation supports the endotoxin-lipoprotein hypothesis⁴⁸ stating that chronic systemic low-grade inflammation connects LDL cholesterol to CRP. There is increasing evidence that changes in serum lipoproteins might be a response to a state of chronic inflammation *secondary* to our current lifestyle that in turn is composed of many factors. Besides the influence of dietary changes, environmental changes such as stress, sleep deprivation and environmental pollution, including smoking, have also been related to chronic inflammation.⁴⁹ It was recently re-emphasised that these so-called gene-environment interactions play important roles in the development of many, if not all, current diseases of civilization,^{50,51} while a primary role for 'faulty' genes, is grossly overestimated.^{52,53}

Common metabolic disorders, such as obesity, type 2 diabetes and the metabolic syndrome, are associated with low-grade inflammation and elevations in acute phase proteins such as CRP.⁵⁴ It has become increasingly clear that insulin resistance develops secondary to systemic inflammation and that the compensatory hyperinsulinaemia aims primarily at balancing glucose homeostasis.^{55,56} The insulin resistant state, induced by pro-inflammatory cytokines, is indispensable for the reallocation of energy-rich substrates. Glucose is conserved for the metabolically highly active brain and for the activated immune system, which both rely on glucose metabolism for their energy supply.⁵⁵ Organs that would normally also use glucose become insulin resistant and use triglycerides and free fatty acids, distributed by the liver and adipose tissue, respectively, as energy sources. At the same time, the lipoprotein profile might act to fight off inflammation and support the repair of tissue damage secondary to the inflammatory reaction.⁵⁷⁻⁶⁶ This is executed via: 1) an increase in cholesterol-rich lipoproteins (mainly LDL and VLDL), which have the ability to bind bacterial lipopolysaccharide (LPS) in proportion to their cholesterol content,^{16,67,68} although the best determinant of the capacity of lipoprotein to bind LPS is a high phospholipid/cholesterol ratio (i.e. surface/volume ratio);⁶⁹ 2) the suppression of reverse cholesterol transport via multiple pathways⁶⁶ (i.e. low HDL); 3) increased oxidation

of LDL and VLDL, while HDL becomes proinflammatory;⁶² 4) increased cholesterol delivery to the immune system,⁶² and 5) the production of small dense LDL particles.⁷⁰ The last-mentioned become enriched in sphingolipids, are poorly cleared by the LDL receptor, cross the endothelial barrier more effectively, bind to the vascular wall intima and are accumulated in macrophages because of their susceptibility to oxidative modification.⁶² Taken together, the proatherogenic dyslipidaemia of the metabolic syndrome is in support of the recovery from inflammation-induced damage.^{48,55} However, when these changes in the lipoprotein profile last for prolonged periods of time, such as in the chronic low-grade inflammation of the metabolic syndrome,¹⁴ they give rise to the development of atherosclerosis.^{62,66}

Taken together that our current lifestyle includes many factors that 1) initiate and propagate inflammation; 2) give rise to an inadequate capacity to terminate inflammatory responses; and 3) lead to insufficient protection from the collateral damage caused by the chronic immune activation. One of these factors is our dietary SAFA intake, which can cause inflammation by their mimicking of a part of bacterial LPS⁴⁸ and/or by providing other pro-inflammatory stimuli.^{67,68,71} Whether dietary SAFA cause inflammation depends on the accumulation of SAFA in the body and not on the dietary SAFA intake *per se*. Accumulation of SAFA can also occur by the synthesis of SAFA from CHO via *de novo* fatty acid synthesis. This mainly occurs in the liver, which secretes these *de novo* synthesised fatty acids as VLDL.^{16,72}

SAFA VS CARBOHYDRATES, THE METABOLIC SYNDROME AND THE IMMUNE SYSTEM

The adverse effects of high SAFA intake on lipid metabolism are particularly noted when SAFA are combined with a high CHO intake. Under these conditions, dietary SAFA are preserved, while the surplus of the consumed CHO is converted to SAFA by hepatic *de novo* fatty acid synthesis. Although the conservation of SAFA during excessive intake of CHO with a high glycaemic index is well known,⁷³⁻⁷⁶ the synthesis of SAFA from (surplus) CHO may not have received sufficient attention. Contrary to widespread belief, *de novo* fatty acid synthesis is not restricted to hypercaloric conditions or to excessive intake of CHO, but also depends on the type of ingested CHO. A low-fat eucaloric diet with a high sugar/starch ratio stimulated *de novo* fatty acid synthesis and increased serum triglycerides in normal weight individuals.⁷² When subjects with the metabolic syndrome, i.e. with pre-existing insulin resistance, were fed either a hypocaloric low-CHO/high-fat diet with high

SAFA content or a hypocaloric high-CHO/low-fat diet with low SAFA content, the low-CHO/high-SAFA diet resulted in *lower* SAFA levels in plasma lipids compared with the high-CHO/low-SAFA diet.^{75,76} Finally, in subjects with the hepatic manifestation of the metabolic syndrome, i.e. non-alcoholic fatty liver disease, 26% of the fatty acids in the liver triglycerides and 23% of the fatty acids in VLDL triglycerides derive from *de novo* fatty acid synthesis in the liver.⁷⁷ Importantly, as much as 25 to 30% of Western adults are suffering from non-alcoholic fatty liver disease⁷⁸ in which the hepatic synthesis of fat, including SAFA, has become independent of the metabolic state, i.e. is independent of the feeding-fasting cycle.⁷⁷ Taken together, SAFA accumulate: 1) under eucaloric conditions in normal weight subjects who consume a CHO-rich diet with high glycaemic index; and 2) under hypocaloric conditions in subjects with the metabolic syndrome and non-alcoholic fatty liver disease who consume CHO-rich diets. Thus CHO, particularly those with a high glycaemic index, and pre-existing insulin resistance are confounding factors in the discussion on the relation between CVD and dietary SAFA. This observation underscores the importance of a renewed discussion about the possible dangers of dietary SAFA.

CONCLUSIONS

The total body of evidence suggests that attention should be shifted from the harmful effects of dietary SAFA *per se*, to the prevention of the accumulation of SAFA in body lipids. This shift would emphasise the importance of reducing dietary CHO, especially CHO with a high glycaemic index, rather than reducing dietary SAFA. The chronic interaction of SAFA with our immune system elicits so-called chronic systemic low-grade inflammation, which underlies the metabolic changes referred to as the (atherogenic) dyslipidaemia of the metabolic syndrome or the lipidaemia of sepsis. The ultimate goal of the ensuing insulin resistance is the re-allocation of energy-rich substrates, such as glucose, to the immune system while the change in our lipoprotein profile aims at the limitation of the inflammatory responses and the repair of the resulting tissue damage. Dietary SAFA belong to the many false triggers of inflammation that result from the conflict between our slowly adapting genome and our rapidly changing lifestyle, but among these many factors they are not the most important. A reduction in the consumption of CHO with a high glycaemic index, *trans*-fatty acids and linoleic acid, and an increased consumption of fish, vegetables and fruit, and a reduction of inactivity, sleep deprivation and chronic stress seem more realistic approaches to fight the current pandemic of cardiovascular disease resulting from chronic systemic low grade inflammation.

REFERENCES

1. Hulshof KFAM, Ocké MC, van Rossum CTM. Resultaten van de Voedselconsumptiepeiling 2003. 2004;RIVM rapport nr 350030002/2004;TNO rapport nr V6000.
2. Hulshof KFAM, Ocké MC. Voedselconsumptiepeilingen 2003; onderzoek bij jongvolwassen Nederlanders. Focus op macrovoedingsstoffen. Ned Tijdschr Klin Chem Labgeneesk. 2005;30:185-91.
3. Dietary Guidelines for Americans 2005. Available at: <http://www.health.gov/dietaryguidelines/dga2005/document/html/chapter6.htm#table10>, 11 June 2011.
4. Keys AB. Seven countries: a multivariate analysis of death and coronary heart disease. London, England: Harvard University Press, Cambridge Massachusetts; 1980.
5. Mensink RP, Zock PL, Kester AD, et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr.* 2003;77:1146-55.
6. Clarke R, Frost C, Collins R, et al. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *BMJ.* 1997;314:112-7.
7. Frantz ID Jr, Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. *Arteriosclerosis.* 1989;9:129-35.
8. Mann GV, Shaffer RD, Rich A. Physical fitness and immunity to heart-disease in Masai. *Lancet.* 1965;2:1308-10.
9. Ravnskov U. A hypothesis out-of-date. the diet-heart idea. *J Clin Epidemiol.* 2002;55:1057-63.
10. Weinberg SL. The diet-heart hypothesis: a critique. *J Am Coll Cardiol.* 2004;43:731-3.
11. Shaper AG, Leonard PJ, Jones KW, et al. Environmental effects on the body build, blood pressure and blood chemistry of nomadic warriors serving in the army in Kenya. *East Afr Med J.* 1969;46:282-9.
12. Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet.* 2007;370:1829-39.
13. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. *N Engl J Med.* 1991;325:373-81.
14. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. *Annu Rev Nutr.* 2005;25:391-406.
15. Feinman RD, Volek JS. Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss. *Nutr Metab (Lond).* 2006;3:24.
16. Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. *Arterioscler Thromb Vasc Biol.* 2008;28:1225-36.
17. Verhoye E, Langlois MR, Asklepios Investigators. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? *Clin Chem Lab Med.* 2009;47:128-37.
18. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. *Arteriosclerosis.* 1983;3:149-59.
19. Richtlijnen goede voeding 2006. 2006; Publicatie nr 2006/21.
20. Richtlijnen goede voeding 2006 - achtergronddocument. 2006; Publicatie nr A06/08.
21. Siri-Tarino PW, Sun Q, Hu FB, et al. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr.* 2010;91:535-46.
22. Scarborough P, Rayner M, van Dis I, et al. Meta-analysis of effect of saturated fat intake on cardiovascular disease: overadjustment obscures true associations. *Am J Clin Nutr.* 2010;92:458,9; author reply 459.
23. Soedamah-Muthu SS, Ding EL, Al-Delaimy WK, et al. Milk and dairy consumption and incidence of cardiovascular diseases and all-cause mortality: dose-response meta-analysis of prospective cohort studies. *Am J Clin Nutr.* 2011;93:158-71.
24. Goldbohm RA, Chorus AM, Galindo Garre F, et al. Dairy consumption and 10-y total and cardiovascular mortality: a prospective cohort study in the Netherlands. *Am J Clin Nutr.* 2011;93:615-27.
25. Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. *Am J Clin Nutr.* 2009;89:1425-32.
26. Jakobsen MU, Dethlefsen C, Joensen AM, et al. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. *Am J Clin Nutr.* 2010;91:1764-8.
27. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation.* 1999;99:779-85.
28. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? *Am J Clin Nutr.* 2011:684-8.
29. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med.* 2010;7:e1000252.
30. Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. *Lipids.* 2010;45:893-905.
31. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. *Circulation.* 2009;119:902-7.
32. Calder PC, Dangour AD, Diekman C, et al. Essential fats for future health. Proceedings of the 9th Unilever Nutrition Symposium, 26-27 May 2010. *Eur J Clin Nutr.* 2010;64 Suppl 4:S1-13.
33. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. *N Engl J Med.* 2006;354:1601-13.
34. Ramsden CE, Hibbeln JR, Majchrzak SF, et al. n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. *Br J Nutr.* 2010;104:1586-600.
35. Biss K, Ho KJ, Mikkelsen B, et al. Some unique biologic characteristics of the Masai of East Africa. *N Engl J Med.* 1971;284:694-9.
36. Ho KJ, Biss K, Mikkelsen B, et al. The Masai of East Africa: some unique biological characteristics. *Arch Pathol.* 1971;91:387-410.
37. Kreijl C.F. van, Knaap A.G.A.C. Ons eten gemeten – Gezonde voeding en veilig voedsel in Nederland. 2004;RIVM rapport nr 270555007.
38. Peeters A, Nusselder WJ, Stevenson C, et al. Age-specific trends in cardiovascular mortality rates in the Netherlands between 1980 and 2009. *Eur J Epidemiol.* 2011;369-73.
39. Scarborough P, Notham KE, Clarke D, et al. Modelling the impact of a healthy diet on cardiovascular disease and cancer mortality. *J Epidemiol Community Health.* 2010.Epub ahead of print.
40. Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. *Circulation.* 2010;122:1637-48.
41. Malik VS, Popkin BM, Bray GA, et al. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation.* 2010;121:1356-64.
42. Hu FB. Are refined carbohydrates worse than saturated fat? *Am J Clin Nutr.* 2010;91:1541-2.
43. Ridker PM. Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease. *Clin Chem.* 2010;56:1186-7.
44. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008;359:2195-207.

45. Heart Protection Study Collaborative Group, Jonathan E, Derrick B, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. *Lancet*. 2011;377:469-76.
46. Despres JP. CRP: star trekking the galaxy of risk markers. *Lancet* 2011;377:441-2.
47. O'Keefe JH, Carter MD, Lavie CJ, et al. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). *Postgrad Med*. 2009;121:113-8.
48. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. *Lancet* 2000;356:930-3.
49. Egger G, Dixon J. Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease. *Obes Rev*. 2010;11:137-49.
50. Pijl H. Obesity: evolution of a symptom of affluence. *Neth J Med*. 2011;69:159-66.
51. Serlie MJ, La Fleur SE, Fliers E. Obesity: is evolution to blame? *Neth J Med*. 2011;69:156-8.
52. Willett WC. Balancing life-style and genomics research for disease prevention. *Science*. 2002;296:695-8.
53. Hemminki K, Lorenzo Bermejo J, Forsti A. The balance between heritable and environmental aetiology of human disease. *Nat Rev Genet*. 2006;7:958-65.
54. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444:860-7.
55. Straub RH, Cutolo M, Buttgerit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. *J Intern Med*. 2010;267:543-60.
56. Straub RH. Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. *Brain Behav Immun*. 2011;25:1-5.
57. Netea MG, Demacker PN, Kullberg BJ, et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. *J Clin Invest*. 1996;97:1366-72.
58. van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, et al. The role of high density lipoprotein in sepsis. *Neth J Med*. 2001;59:102-10.
59. Hudgins LC, Parker TS, Levine DM, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. *J Lipid Res*. 2003;44:1489-98.
60. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. *Clin Microbiol Rev*. 2003;16:379-414.
61. van Leeuwen HJ, Heezius EC, Dallinga GM, et al. Lipoprotein metabolism in patients with severe sepsis. *Crit Care Med*. 2003;31:1359-66.
62. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J Lipid Res*. 2004;45:1169-96.
63. Murch O, Collin M, Hinds CJ, et al. Lipoproteins in inflammation and sepsis. I. Basic science. *Intensive Care Med*. 2007;33:13-24.
64. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. *Intensive Care Med*. 2007;33:25-35.
65. Feingold KR, Grunfeld C. The role of HDL in innate immunity. *J Lipid Res*. 2011;52:1-3.
66. Feingold KR, Grunfeld C. The acute phase response inhibits reverse cholesterol transport. *J Lipid Res*. 2010;51:682-4.
67. Chait A, Kim F. Saturated fatty acids and inflammation: who pays the toll? *Arterioscler Thromb Vasc Biol*. 2010;30:692-3.
68. Schwartz EA, Zhang WY, Karnik SK, et al. Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. *Arterioscler Thromb Vasc Biol*. 2010;30:802-8.
69. Kitchens RL, Thompson PA, Munford RS, et al. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. *J Lipid Res*. 2003;44:2339-48.
70. Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. *Cardiol Rev*. 2006;14:125-35.
71. Lee JY, Zhao L, Hwang DH. Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. *Nutr Rev*. 2010;68:38-61.
72. Hudgins LC, Hellerstein MK, Seidman CE, et al. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. *J Lipid Res*. 2000;41:595-604.
73. Forsythe CE, Phinney SD, Fernandez ML, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. *Lipids*. 2008;43:65-77.
74. Volek JS, Ballard KD, Silvestre R, et al. Effects of dietary carbohydrate restriction versus low-fat diet on flow-mediated dilation. *Metabolism*. 2009;58:1769-77.
75. Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. *Lipids*. 2009;44:297-309.
76. Forsythe CE, Phinney SD, Feinman RD, et al. Limited effect of dietary saturated fat on plasma saturated fat in the context of a low carbohydrate diet. *Lipids*. 2010;45:947-62.
77. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest*. 2005;115:1343-51.
78. Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. *Curr Opin Clin Nutr Metab Care*. 2008;11:766-73.